Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal.

CONCLUSIONS: Gordon et al conclude that risankizumab has a higher efficacy than placebo and ustekinumab in the treatment of moderate-to-severe chronic plaque psoriasis, and that the adverse event profiles were similar across all treatment groups. This article is protected by copyright. All rights reserved. PMID: 30632140 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research